Al Hammadi Holding — Capital/Financing Update 2021

Jul 11, 2021

Al Hammadi Company for Development and Investment announces that it has signed an agreement to purchase 35% of Sudair Pharmaceutical Company

4007 · 11/07/2021 08:27:21 · Announcement #64101 · View on Saudi Exchange

Al Hammadi Company for Development and Investment announces that it has signed an agreement to purchase 35% of Sudair Pharmaceutical Company

Element List	Explanation
Introduction	Al Hammadi Company for Development and Investment is pleased to announce to the shareholders that it has signed an agreement to purchase the entire Stake shares of the Gulf Investment Corporation (GIC) , which represents 35% of Sudair Pharmaceuticals Company, the owner and developer of Sudair Complex for Specialized Pharmaceutical Industries
Date of signing the Memorandum of Understanding	2021-07-09 Corresponding to 1442-11-29
Memorandum Duration	3 months
Name of the Counterparty	Gulf Investments Corporation
Name of Financial Advisor of Each Party	Aldukheil Financial Group
Major Terms in the Memorandum	Completion of the due diligence examination of the company's financial, legal, administrative and operational conditions and Status
Related Parties	none
Actions to be Taken by the Company during the Memorandum’s Duration	Appointing consultants to carry out the financial examination and legal examination of due diligence
Approvals	Purchasing procedures are subject to the approval of the relevant authorities
Additional Information	The cancer drugs manufacturing plant represents the first stage of Sudair Pharmaceuticals complex, which is considered the largest pharmaceutical project specialized in the manufacturing of cancer treatments (oral and intravenous) in the Kingdom of Saudi Arabia.

The project is located on an area of 77 thousand square meters, and includes in addition to administrative buildings, research centers, and a training academy.

The acquisition is in line with Al Hammadi Company’s growth plans and the Kingdom’s Vision 2030 to nationalize and localize advanced industries and technologies, as well as to provide an opportunity to benefit from and capitalize on the significant growth potential of the manufacturing and distribution of specialized drugs

The Capital Market Authority and Saudi Exchange take no responsibility for the contents of this disclosure, make no representations as to its accuracy or completeness, and expressly disclaim any liability whatsoever for any loss arising from, or incurred in reliance upon, any part of this disclosure, and the issuer accepts full responsibility for the accuracy of the information contained in it and confirms, having made all reasonable enquiries, that to the best of their knowledge and belief, there are no other facts or information the omission of which would make the disclosure misleading, incomplete or inaccurate.